{
  "id": 9245769,
  "title": "Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts",
  "url": "https://urgent.news/2026/09/23/rising-us-scrutiny-on-clinical-trials-could-threaten-chinas-biotech",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-23T02:00:09.000Z",
  "source": {
    "name": "South China Morning Post",
    "slug": "south-china-morning-post",
    "url": "https://www.scmp.com/business/markets/article/3368445/rising-us-scrutiny-clinical-trials-could-threaten-chinas-biotech-advantage-analysts"
  },
  "original_language": "en",
  "account": null,
  "summary": "China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about American pharmaceutical companies’ growing reliance on conducting…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "SCMP Business",
        "title": "Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts",
        "url": "https://urgent.news/2026/09/23/rising-us-scrutiny-on-clinical-trials-could-threaten-chinas-biotech-9245954",
        "published": "2026-09-23T02:00:09.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}